Salarius Pharmaceuticals (NASDAQ:SLRX)’s stock price dropped 8.1% during mid-day trading on Tuesday . The company traded as low as $0.56 and last traded at $0.57, approximately 198,700 shares were traded during mid-day trading. A decline of 37% from the average daily volume of 314,830 shares. The stock had previously closed at $0.62.
Separately, Zacks Investment Research raised Salarius Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Tuesday, February 18th.
The company has a market capitalization of $2.93 million, a P/E ratio of -0.08 and a beta of 1.90. The stock’s fifty day moving average is $0.91.
A hedge fund recently bought a new stake in Salarius Pharmaceuticals stock. Geode Capital Management LLC purchased a new stake in Salarius Pharmaceuticals (NASDAQ:SLRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,330 shares of the company’s stock, valued at approximately $69,000. Geode Capital Management LLC owned 0.41% of Salarius Pharmaceuticals at the end of the most recent quarter. 4.94% of the stock is currently owned by hedge funds and other institutional investors.
About Salarius Pharmaceuticals (NASDAQ:SLRX)
Salarius Pharmaceuticals, Inc a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers.
Read More: What is the CAC 40 Index
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.